CD8A and non-small cell lung carcinoma: The chemo-drug paclitaxel has been shown to induce proinflammatory responses which promote tumor progression and also blunt the sensitivity to antitumor drugs.57 PCB chemotherapy (paclitaxel, carboplatin and bevacizumab combination) increases the proliferation of peripheral blood CD8+ effector T cells in non-small cell lung cancer patients.